文章核心观点 - 根据原告的集体诉讼,Agenus公司在2023年1月23日至2024年7月17日期间做出了虚假陈述和隐瞒信息,误导了投资者[1][2] - 具体而言,公司虚假宣传了其免疫肿瘤产品botensilimab和balstilimab的联合疗法的疗效,夸大了其临床结果、监管和商业前景[2] 根据目录分类总结 案件概况 - 该集体诉讼针对Agenus公司2023年1月23日至2024年7月17日期间的证券欺诈行为[1] - 投资者如果在此期间遭受损失,可以在2024年11月5日之前申请担任首席原告[2] - 作为集体成员,投资者可以获得赔偿,无需支付任何费用[2] 原告律师事务所简介 - Levi & Korsinsky律师事务所在过去20年中为受害股东赢得了数亿美元的赔偿[3] - 该所在复杂证券诉讼方面拥有丰富的专业经验,在美国证券集体诉讼排名中连续7年位列前50[3]

NEW YORK, Sept. 19, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN).Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=103499&from=4 CLASS PERIOD: January 23, 2023 to July 17, 202 ...

NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN). Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=103181&from=3 CLASS PERIOD: January 23, 2023 to July ...

Faruqi & Faruqi Reminds Agenus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 5, 2024 - AGENFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Agenus To Contact Him Directly To Discuss Their OptionsSeptember 17, 2024 10:06 AM EDT | Source: Faruqi & Faruqi LLPIf you suffered losses exceeding $50,000 in Agenus between January 23, 2023 and July 17, 2024 and would like to dis ...

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Agenus investors who were adversely affected by alleged securities fraud between January 23, 2023 and July 17, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?pri ...

NEW YORK, Sept. 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN).Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=102409&from=4 CLASS PERIOD: January 23, 2023 to July 17, 202 ...

NEW YORK, Sept. 12, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Agenus Inc. (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 5, 2024.So What: If you purchased Agenus securities during the Class Period you may ...

NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Agenus Inc. (“Agenus” or the “Company”) (NASDAQ: AGEN) in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Agenus securities between January 23, 2023 and July 17, 2024, both dates inclusive (the “Class Period”). Investors have until ...

NEWTOWN, Pa., Sept. 11, 2024 /PRNewswire/ -- Edelson Lechtzin LLP, a leading class action law firm, is investigating securities fraud claims on behalf of all investors of Agenus, Inc. ("Agenus") (NASDAQ: AGEN) between January 23, 2023, and July 17, 2024, inclusive (the "Class Period").Investors who purchased Agenus stock may move the U.S. District Court for the District of Massachusetts to appoint them as lead plaintiff, no later than November 5, 2024. Please contact Edelson Lechtzin LLP to discuss your inv ...

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities who purchased or otherwise acquired Agenus Inc. (NASDAQ: AGEN) securities between January 23, 2023 and July 17, 2024. Agenus is a clinical-stage biotechnology company that discovers and develops immuno-oncology (“I-O”) products in the U.S. and internationally. Among other product candidates, the Company is developing balstilimab, an anti-PD-1 antagonist th ...